Spots Global Cancer Trial Database for unresectable solid neoplasm

Every month we try and update this database with for unresectable solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression	NCT04957615	Metastatic Mali... Unresectable So...	Nivolumab	-	M.D. Anderson Cancer Center
Study of GNX102 in Patients With Advanced Solid Tumors	NCT04250597	Solid Tumor Metastatic Canc... Advanced Cancer Unresectable So...	GNX102 GNX102	18 Years -	GlycoNex, Inc.
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02408861	Advanced Malign... Anal Carcinoma HIV Infection Kaposi Sarcoma Lung Carcinoma Metastatic Mali... Recurrent Class... Refractory Clas... Unresectable So...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ipilimumab Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction	NCT03217253	Ann Arbor Stage... Ann Arbor Stage... Metastatic Mali... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable So...	Laboratory Biom... Pharmacological... Tazemetostat	18 Years -	National Cancer Institute (NCI)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	NCT03218826	Advanced Breast... Advanced Malign... Advanced Prosta... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Metastatic Brea... Metastatic Mali... Metastatic Pros... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Triple-Negative... Unresectable So...	Docetaxel Laboratory Biom... Pharmacological... PI3Kbeta Inhibi...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery	NCT03087591	Metastatic Mali... Metastatic Soli... Recurrent Color... Recurrent Pancr... Recurrent Solid... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable So...	Laboratory Biom... siRNA-transfect...	18 Years -	Wake Forest University Health Sciences
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02503709	Advanced Malign... Metastatic Mali... Unresectable So...	CDK Inhibitor A... Laboratory Biom... Onalespib Pharmacological...	18 Years -	National Cancer Institute (NCI)
Ipilimumab and Imatinib Mesylate in Advanced Cancer	NCT01738139	Advanced Malign... C-KIT Tyrosine ... Clinical Stage ... Metastatic Gast... Metastatic Mali... Metastatic Mela... Pathologic Stag... Unresectable Me... Unresectable So...	Imatinib Mesyla... Ipilimumab	15 Years -	M.D. Anderson Cancer Center
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes	NCT03061188	Advanced Solid ... Aggressive Non-... Recurrent Solid... Refractory Mant... T-Cell Non-Hodg... Unresectable So...	Laboratory Biom... Nivolumab Pharmacological... Veliparib	18 Years -	Northwestern University
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction	NCT02070549	Advanced Malign... Metastatic Mali... Metastatic Mali... Unresectable So...	Trametinib	18 Years -	National Cancer Institute (NCI)
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery	NCT01787500	BRAF NP_004324.... KRAS wt Allele Metastatic Mali... Stage IV Colore... Stage IVA Color... Stage IVB Color... Unresectable So...	Cetuximab Irinotecan Hydr... Laboratory Biom... Pharmacological... Vemurafenib	18 Years -	M.D. Anderson Cancer Center
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression	NCT04957615	Metastatic Mali... Unresectable So...	Nivolumab	-	M.D. Anderson Cancer Center
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Ipilimumab and Imatinib Mesylate in Advanced Cancer	NCT01738139	Advanced Malign... C-KIT Tyrosine ... Clinical Stage ... Metastatic Gast... Metastatic Mali... Metastatic Mela... Pathologic Stag... Unresectable Me... Unresectable So...	Imatinib Mesyla... Ipilimumab	15 Years -	M.D. Anderson Cancer Center
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin	NCT02535312	Advanced Malign... Advanced Perito... Advanced Pleura... Recurrent Perit... Recurrent Pleur... Refractory Mali... Unresectable So...	Cisplatin Methoxyamine Pemetrexed Diso...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: